Multicenter, double-blind, randomized, intra- individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in mri of brain tumors at 3 tesla

Zoran Rumboldt, Howard A. Rowley, Fred Steinberg, Joseph A Maldjian, Jordi Ruscalleda, Lars Gustafsson, Stefano Bastianello

Research output: Contribution to journalArticle

31 Scopus citations


Purpose: To prospectively compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MRI of brain lesions at 3 Tesla (T). Materials and Methods: Forty-six randomized patients underwent a first examination with gadobenate dimeglumine (n = 23) or gadopentetate dimeglumine (n = 23) and then, after 2-7 days, a second examination with the other agent. Contrast administration (volume, rate), sequence parameters (T1wSE; T1wGRE), and interval between injection and image acquisition were identical for examinations in each patient. Three blinded neuroradiologists evaluated images qualitatively (lesion delineation, lesion enhancement, global preference) and quantitatively (lesion-to-brain ratio [LBR], contrast- to-noise ratio [CNR], % lesion enhancement). Differences were assessed using Wilcoxon's signed-rank test. Reader agreement was determined using kappa (k) statistics. Results: There were no demographic differences between groups. The three readers preferred gadobenate dimeglumine globally in 22 (53.7%), 21 (51.2%), and 27 (65.9%) patients, respectively, compared with 0, 1, and 0 patients for gadopentetate dimeglumine. Similar significant (P < 0.001) preference was expressed for lesion border delineation and enhancement. Reader agreement was consistently good (k = 0.48-0.64). Significantly (P < 0.05) higher LBR (+43.5- 61.2%), CNR (+51.3-147.6%), and % lesion enhancement (+45.9-49.5%) was noted with gadobenate dimeglumine. Conclusion: Brain lesion depiction at 3T is significantly improved with 0.1 mmol/kg gadobenate dimeglumine.

Original languageEnglish (US)
Pages (from-to)760-767
Number of pages8
JournalJournal of Magnetic Resonance Imaging
Issue number4
StatePublished - Apr 1 2009



  • Brain tumor imaging
  • Comparative studies
  • Gadobenate dimeglu- Mine
  • High field mri

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this